echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > WHO guidelines are heavily updated, and new initiatives are being taken to treat Cryptococcus meningitis in HIV-infected patients

    WHO guidelines are heavily updated, and new initiatives are being taken to treat Cryptococcus meningitis in HIV-infected patients

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    For medical professionals only

    The new initiative is less toxic and less monitored

    On 27 June 2022, the World Health Organization (WHO) published an update to the Guidelines for the Diagnosis, Prevention and Management of Cryptococcosis in Adults, Adolescents and Children Living with HIV[1


    A single high dose of amphotericin B liposomes (L-AmB) is strongly recommended in this update as a component of the preferred induction regimen for the treatment of Cryptococcus meningitis (CM) in HIV-infected patients [10 mg/kg L-AmB+5-FC (100 mg/kg·d*14d)+FLU (1200 mg/day*14d)].


    Watch the video to learn more about Professor Lu's wonderful reviews!



    In the treatment of Cryptococcus meningitis, Cryptococcus meningitis (CM), which races





    Among the secondary endpoints, the mean rates of Cryptococcal clearance in cerebrospinal fluid in the L-AmB and DAmB groups within 14 days were -0.


    Within 21 days of initiation of antifungal therapy, fewer people in the L-AmB group experienced grade 3-4 adverse events [210 (50.




    1.


    2.


    3.


    Get more of the latest literature, guidelines and cutting-edge information in the field of hepatitis, AIDS, antifungals, and interact
    with AI medical assistant "Xiaozhi", welcome to pay attention to the "JizhiYi" reference:
    [1] World Health, O.
    , Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV.
    2022, Geneva: World Health Organization.
    [2] Rajasingham, R.
    , et al.
    , Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.
    Lancet Infect Dis, 2017.
    17(8): p.
    873-881.
    [3] Pasquier, E.
    , et al.
    , Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review.
    Clin Infect Dis, 2018.
    66(7): p.
    1122-1132.
    [4] Stott, K.
    E.
    , et al.
    , Cryptococcal meningoencephalitis: time for action.
    The Lancet Infectious Diseases, 2021.
    21(9): p.
    e259-e271.
    [5] Wu, X.
    and Y.
    Shen, Management of human immunodeficiency virus-associated cryptococcal meningitis: Current status and future directions.
    Mycoses, 2019.
    62(10): p.
    874-882.
    [6] Jarvis, J.
    N.
    , et al.
    , Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
    N Engl J Med, 2022.
    386(12): p.
    1109-1120.
    [7] Stone, N.
    R.
    , et al.
    , Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.
    Drugs, 2016.
    76(4): p.
    485-500.
    [8] Hamill, R.
    J.
    , et al.
    , Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
    Clin Infect Dis, 2010.
    51(2): p.
    225-32.
    [9] Chen, M.
    , N.
    Xu, and J.
    Xu, Cryptococcus Neoformans Meningitis Cases Among China's HIV-Infected Population may have been Severely Under-Reported.
    Mycopathologia, 2020.
    185(6): p.
    971-974.
    [10] Fang, L.
    F.
    , et al.
    , Clinical and microbiological characteristics of cryptococcosis at an university hospital in China from 2013 to 2017.
    Braz J Infect Dis, 2020.
    24(1): p.
    7-12.
    [11] Pang, W.
    , et al.
    , Prevalence of Opportunistic Infections and Causes of Death among Hospitalized HIV-Infected Patients in Sichuan, China.
    Tohoku J Exp Med, 2018.
    244(3): p.
    231-242.

    This information is for medical and scientific reference only and is not recommended for use in any way that is inconsistent with the prescribing information approved in your country,
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.